Two Syncona-backed players join forces to take on retinal gene therapies
With ambitions to build an eye gene-therapy powerhouse, UK-based Gyroscope Therapeutics is swallowing US-based device maker Orbit Biomedical, which is focused on sub-retinal surgical delivery …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.